Linaclotide (Constella®)

Assessment Status Rapid Review Complete
Drug Linaclotide
Brand Constella®
Indication For the treatment of symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults.
Assessment Process
Rapid review commissioned 28/05/2013
Rapid review completed 28/06/2013
Rapid review outcome Full Pharmacoeconomic Assessment Not Recommended

Linaclotide (Constella®) is to be reimbursed under the Community Drugs Schemes subject to conditions.